exatecan mesylate

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pancreatic Cancer

Conditions

Pancreatic Cancer

Trial Timeline

Jun 1, 1999 → Apr 1, 2005

NCT ID

NCT00003951

About exatecan mesylate

exatecan mesylate is a phase 2 stage product being developed by Daiichi Sankyo for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00003951. Target conditions include Pancreatic Cancer.

What happened to similar drugs?

9 of 20 similar drugs in Pancreatic Cancer were approved

Approved (9) Terminated (4) Active (11)

✅DalteparinEisaiApproved

✅CREONAbbVieApproved

✅Pancrelipase + PlaceboAbbVieApproved

✅Pancrelipase CapsulesAbbVieApproved

✅Chromogranin ANovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

✅everolimusNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00055952	Phase 2	Completed	Jan 1, 2003	Apr 1, 2006	Sarcoma
NCT00055939	Phase 2	Completed	Jan 1, 2003	Apr 1, 2006	Sarcoma
NCT00017212	Phase 2	Completed	Apr 1, 2001	Sep 1, 2003	Esophageal Cancer
NCT00005938	Phase 2	Completed	Mar 1, 2000	Apr 1, 2005	Extrahepatic Bile Duct Cancer
NCT00004866	Phase 2	Completed	Jan 1, 2000	Sep 1, 2003	Cervical Cancer
NCT00004108	Phase 2	Completed	Sep 1, 1999	Apr 1, 2005	Liver Cancer
NCT00004060	Phase 2	Completed	Jul 1, 1999	Sep 1, 2000	Fallopian Tube Cancer
NCT00004046	Phase 2	Completed	Jun 1, 1999	Apr 1, 2002	Breast Cancer
NCT00003951	Phase 2	Completed	Jun 1, 1999	Apr 1, 2005	Pancreatic Cancer
NCT00004045	Phase 2	Completed	Jun 1, 1999	Aug 1, 2001	Prostate Cancer
NCT00004047	Phase 1	Completed	Jun 1, 1999	Apr 1, 2005	Leukemia

Competing Products

20 competing products in Pancreatic Cancer

See all competitors

Product	Company	Stage	Hype Score
CD40 agonist mitazalimab in combination with chemotherapy	Alligator Bioscience AB	Phase 1/2	26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	18
pemetrexed	Eli Lilly	Phase 2	35
mFOLFIRINOX + Ramucirumab	Eli Lilly	Phase 2	35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359	Perspective Therapeutics	Phase 1/2	33
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	29
enzastaurin + gemcitabine	Eli Lilly	Phase 2	35
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4	Eli Lilly	Phase 1	29
Ramucirumab	Eli Lilly	Phase 1/2	32
GEMZAR + ALIMTA	Eli Lilly	Phase 3	40
CS-1008 (humanized anti-DR5 antibody) + gemcitabine	Daiichi Sankyo	Phase 2	35
exatecan mesylate + gemcitabine hydrochloride	Daiichi Sankyo	Phase 3	40
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	42
AGS-1C4D4 + gemcitabine	Astellas Pharma	Phase 2	35
erlotinib + gemcitabine + nab-paclitaxel	Astellas Pharma	Phase 1	29
erlotinib hydrochloride + gemcitabine hydrochloride	Astellas Pharma	Phase 1	29
AGS-1C4D4 + Gemcitabine	Astellas Pharma	Phase 2	35
Tarceva (erlotinib HCl, OSI-774)	Astellas Pharma	Phase 3	40
Enzalutamide + Gemcitabine + Nab-paclitaxel	Astellas Pharma	Phase 1	29